中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
22期
3443-3444,3445
,共3页
胃息肉%大肠息肉%内镜下黏膜切除术
胃息肉%大腸息肉%內鏡下黏膜切除術
위식육%대장식육%내경하점막절제술
Gastric polyps%Colorectal polyps%Endoscopic mucosal resection
目的:探讨内镜下黏膜切除术治疗胃及大肠息肉的临床治疗效果。方法收集172例胃及大肠息肉患者,采用随机数字表法将其分为观察组与对照组各86例,其中观察组给予内镜下黏膜切除术( EMR),对照组给予常规治疗手段进行手术,对比两组临床疗效及不良反应发生情况。结果治疗后,观察组总有效率为96.51%,显著高于对照组的70.93%(χ2=15.73,P<0.05);观察组术后不良反应发生率为22.09%,明显低于对照组的47.67%(χ2=31.65,P<0.05)。结论对于胃及大肠息肉采用内镜下黏膜切除术治疗,不仅可以取得较好的临床疗效,而且不良反应发生情况亦较低。
目的:探討內鏡下黏膜切除術治療胃及大腸息肉的臨床治療效果。方法收集172例胃及大腸息肉患者,採用隨機數字錶法將其分為觀察組與對照組各86例,其中觀察組給予內鏡下黏膜切除術( EMR),對照組給予常規治療手段進行手術,對比兩組臨床療效及不良反應髮生情況。結果治療後,觀察組總有效率為96.51%,顯著高于對照組的70.93%(χ2=15.73,P<0.05);觀察組術後不良反應髮生率為22.09%,明顯低于對照組的47.67%(χ2=31.65,P<0.05)。結論對于胃及大腸息肉採用內鏡下黏膜切除術治療,不僅可以取得較好的臨床療效,而且不良反應髮生情況亦較低。
목적:탐토내경하점막절제술치료위급대장식육적림상치료효과。방법수집172례위급대장식육환자,채용수궤수자표법장기분위관찰조여대조조각86례,기중관찰조급여내경하점막절제술( EMR),대조조급여상규치료수단진행수술,대비량조림상료효급불량반응발생정황。결과치료후,관찰조총유효솔위96.51%,현저고우대조조적70.93%(χ2=15.73,P<0.05);관찰조술후불량반응발생솔위22.09%,명현저우대조조적47.67%(χ2=31.65,P<0.05)。결론대우위급대장식육채용내경하점막절제술치료,불부가이취득교호적림상료효,이차불량반응발생정황역교저。
Objective To investigate therapeutic effects of endoscopic mucosal resection( EMR) on gastric polyps and colorectal polyps.Methods 172 cases of elderly patients with early gastric and colorectal polyps were col-lected.They were divided into the observation group and control group by random number table,each group 86 cases. The observation group were treated with EMR,the control group were received conventional treatment for surgery.The clinical efficacy and adverse events were compared.Results The total effective rate of the observation group was 96.51%,significantly higher than 70.93% in the control group (χ2 =15.73,P<0.05);the postoperative adverse reactions in the observation group was 22.09%,significantly lower than 47.67% in the control group (χ2 =31.65, P<0.05).Conclusion For patients with pre-senile and senile stomach and colon polyps,the application of endo-scopic mucosal resection in the treatment not only can achieve better clinical efficacy, but also lower incidence of adverse reactions.